|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0021747,
umls-concept:C0024301,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0055598,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0332283,
umls-concept:C1413947,
umls-concept:C1442989,
umls-concept:C1707455,
umls-concept:C1831743,
umls-concept:C2603343
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2006-10-5
|
|
pubmed:abstractText |
The purpose of this study is to compare our standard chemotherapy regimen (CHVP [cyclophosphamide, doxorubicin, teniposide, and prednisone]) plus interferon with 4 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by high-dose therapy with autologous stem cell transplantation (ASCT) in treatment-naive patients with advanced follicular lymphoma. Four hundred one patients were included from July 1994 to March 2001: 209 received 12 cycles of CHVP plus interferon alpha for 18 months (CHVP-I arm) and 192 received 4 cycles of CHOP followed by high-dose therapy (HDT) with total body irradiation and ASCT (CHOP-HDT arm). Overall response rates were similar in both groups (79% and 78% after induction chemotherapy, respectively). One hundred thirty-one of the 150 patients eligible for HDT underwent transplantation (87%). Intent-to-treat analysis after a median follow-up of 7.5 years showed that there was no difference between the 2 arms for overall survival (P = .53) or event-free survival (P = .11). Patients with a complete response at the end of the induction therapy had a statistically longer event-free survival and overall survival (P = .02 and < .001, respectively). After long-term follow-up, our study showed that there was no statistically significant benefit in favor of first-line high-dose therapy in patients with follicular lymphoma. High-dose therapy should be reserved for relapsing patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
pubmed-author:BelangerCoralieC,
pubmed-author:BouabdallahRedahR,
pubmed-author:BricePaulineP,
pubmed-author:BrousseNicoleN,
pubmed-author:CoiffierBertrandB,
pubmed-author:DoyenChantalC,
pubmed-author:FeugierPierreP,
pubmed-author:HaiounCorinneC,
pubmed-author:MounierNicolasN,
pubmed-author:SallesGillesG,
pubmed-author:SebbanCatherineC,
pubmed-author:TillyHerveH
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
108
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2540-4
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16835383-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16835383-Belgium,
pubmed-meshheading:16835383-Combined Modality Therapy,
pubmed-meshheading:16835383-Cyclophosphamide,
pubmed-meshheading:16835383-Doxorubicin,
pubmed-meshheading:16835383-Female,
pubmed-meshheading:16835383-France,
pubmed-meshheading:16835383-Humans,
pubmed-meshheading:16835383-Interferon Type I,
pubmed-meshheading:16835383-Lymphoma, Follicular,
pubmed-meshheading:16835383-Male,
pubmed-meshheading:16835383-Middle Aged,
pubmed-meshheading:16835383-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:16835383-Prednisone,
pubmed-meshheading:16835383-Prognosis,
pubmed-meshheading:16835383-Recombinant Proteins,
pubmed-meshheading:16835383-Teniposide,
pubmed-meshheading:16835383-Transplantation, Autologous,
pubmed-meshheading:16835383-Treatment Outcome,
pubmed-meshheading:16835383-Vincristine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
|
|
pubmed:affiliation |
Centre Léon Bérard, 28 Rue Laennec, 69008 Lyon, France. sebban@lyon.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
